
GlycoMimetics Inc (CBIO) Stock Forecast & Price Target
GlycoMimetics Inc (CBIO) Analyst Ratings
Bulls say
Crescent Biopharma is a promising biopharmaceutical company with a strong pipeline featuring CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody, and two potential blockbuster ADC programs in CR-002 and CR-003. The risks to achieving our price target and rating for CBIO include clinical and regulatory failures for CR-001, potential commercial challenges, and potential M&A risks. However, we view CR-001 as a promising clinical asset and remain interested in Crescent's other programs.
Bears say
Crescent Biopharma is a biopharmaceutical company with a focus on developing therapeutics for solid tumors. While their pipeline product CR-001 may have the potential for improved clinical efficacy and safety, the recent Phase 3 clinical trial results comparing it to ivonescimab (a bispecific anti-PD-1/anti-VEGF antibody) showed similar efficacy. Additionally, there are concerns about the company's ability to compete with other oncology therapies, such as Keytruda and LM-299, which could limit their potential sales and market share.
This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.
GlycoMimetics Inc (CBIO) Analyst Forecast & Price Prediction
Start investing in GlycoMimetics Inc (CBIO)
Order type
Buy in
Order amount
Est. shares
0 shares